Microdosing is the practice of taking a very small amount of a psychedelic substance, typically one-tenth to one-twentieth of a recreational dose, on a regular schedule. The goal is not to trip or hallucinate but to take a dose low enough that its effects stay below the threshold of conscious perception. People who microdose report subtle shifts in mood, focus, and creative thinking over days and weeks, though the science behind these claims is still catching up to the enthusiasm.
Typical Substances and Doses
The two most common substances used for microdosing are psilocybin (the active compound in “magic mushrooms”) and LSD. A microdose of LSD falls between 10 and 20 micrograms, compared to 100 to 200 micrograms for a full psychedelic experience. For psilocybin mushrooms, a microdose is roughly 0.3 to 0.5 grams of dried mushrooms, a fraction of the 2 to 5 grams typically associated with a full trip. In pure psilocybin terms, research places the microdose range at about 1 to 3 milligrams, versus the 15 milligrams commonly used in clinical trials.
At these low levels, you should not experience visual distortions, significant shifts in consciousness, or any effects that interfere with your ability to work, drive, or carry on a normal day. If you notice obvious perceptual changes, the dose is too high to be considered a microdose.
How People Schedule It
Most microdosing follows a structured cycle rather than daily use. The most widely referenced schedule, proposed by psychedelic researcher James Fadiman, involves one dosing day followed by two days off. So you might dose on Monday, skip Tuesday and Wednesday, and dose again on Thursday. The off days are considered important both for avoiding tolerance buildup and for observing any lingering effects.
People follow these cycles for anywhere from a single week to several months. Some report continuing for years, though longer-term use raises safety questions that haven’t been well studied.
What People Report Feeling
A University of Toronto study collected reports from nearly 300 self-identified microdosers and organized the most commonly cited benefits into categories. Improved mood topped the list at 27 percent of reports, encompassing both general well-being and reduced feelings of depression. Focus came in at 15 percent, creativity at 13 percent, and a sense of self-efficacy (feeling more capable and motivated) at 11 percent.
Creativity, in this context, doesn’t just mean artistic output. Participants described greater curiosity, more flexible thinking, and increased openness to new ideas. These are the kinds of effects that have made microdosing popular in tech and creative industries, where people hope for a cognitive edge without the disruption of a full psychedelic experience.
What Controlled Studies Actually Show
The picture gets more complicated when researchers test microdosing against a placebo under controlled conditions. A 2024 rapid review of placebo-controlled studies found that LSD microdoses do produce measurable changes in neurobiology, physiology, and subjective experience compared to placebo. LSD microdosing consistently increased feelings of vigor and energy across multiple studies. There were also intriguing hints of cognitive effects, including altered time perception and fewer attentional lapses.
For mood and mental health, though, the findings are mixed. One study found that participants with relatively high rates of depressive symptoms showed reduced depression after an LSD microdose but not after placebo. However, several other studies found no difference in depression, anxiety, or stress scores between microdosing and placebo groups, whether using LSD or psilocybin. Studies also failed to find consistent evidence that microdosing improves performance on standard cognitive tests, creativity tasks, or measures of suggestibility.
One of the most telling findings involves expectation. A large self-blinding study found that participants’ beliefs about what they had taken had a stronger influence on their reported outcomes than whether they actually received a microdose or a placebo. People who correctly guessed they had taken a real dose reported greater effects than those who remained uncertain. That said, expectations only accounted for 5 to 8 percent of the variance in outcomes, suggesting they’re a contributing factor but not the whole story. The honest summary is that microdosing likely does something, but separating genuine pharmacological effects from the powerful influence of belief and expectation remains one of the biggest challenges in this research.
How It Works in the Brain
Psychedelics like LSD and psilocybin work primarily by activating serotonin receptors in the brain, specifically a type called 5-HT2A receptors. These receptors play a key role in mood regulation and perception. At full doses, their activation produces the dramatic shifts in consciousness people associate with tripping. At microdose levels, the activation is far more subtle.
A 2023 study published in Science revealed something surprising about this mechanism. The researchers found that psychedelics promote the brain’s ability to form new connections (neuroplasticity) by activating serotonin receptors located inside brain cells, not just the ones on the cell surface. This is different from how the brain’s own serotonin works, which may explain why psychedelics can trigger plasticity in ways that ordinary serotonin signaling does not. Whether microdoses activate this same pathway strongly enough to produce meaningful neuroplastic changes is still an open question.
Safety Concerns
Because microdosing involves such low doses, many people assume it’s risk-free. The acute risks are indeed minimal compared to full-dose psychedelic use, but the long-term picture is less clear, particularly for people who microdose for months or years.
The most specific concern involves heart health. Both LSD and psilocybin share structural similarities with drugs that are known to cause cardiac fibrosis and heart valve damage when taken regularly. These include older medications like methysergide and fenfluramine, which were pulled from the market partly because of heart valve problems. The mechanism involves chronic activation of a specific serotonin receptor (5-HT2B) found in heart tissue. A review in the Journal of Psychopharmacology flagged this as a concern worth investigating, noting that repeated dosing over months or years could theoretically raise the risk. No studies have yet confirmed or ruled out heart valve changes in human microdosers, but the biological plausibility is enough that researchers are calling for cardiac monitoring in future studies.
Other commonly reported downsides include increased anxiety on dosing days, difficulty sleeping if the dose is taken too late, and occasional headaches. People with a personal or family history of psychotic disorders are generally advised to avoid psychedelics at any dose, as serotonin receptor activation can exacerbate those conditions.
Legal Status
Psilocybin and LSD remain Schedule I controlled substances under U.S. federal law, meaning possession is illegal regardless of the amount. However, a growing number of states and cities have changed their approach at the local level.
Oregon became the first state to legalize psilocybin-assisted therapy in 2020 and simultaneously decriminalized personal possession of small amounts of all drugs, reclassifying it as a civil violation with a maximum $100 fine. Colorado followed in 2022, passing Proposition 122 to legalize and regulate psychedelics and treatment centers for their use. Denver had already become the first U.S. city to deprioritize law enforcement for psilocybin possession back in 2019.
Beyond those statewide changes, dozens of cities have passed resolutions making personal possession of psychedelics the lowest law enforcement priority. These include Oakland, Santa Cruz, Berkeley, and San Francisco in California; Cambridge, Somerville, and Salem in Massachusetts; Ann Arbor, Detroit, and Hazel Park in Michigan; Seattle, Olympia, and Tacoma in Washington; and Minneapolis in Minnesota. Deprioritization does not make possession legal. It signals to police and prosecutors that these cases should be at the bottom of the enforcement pile.
Outside the U.S., the legal landscape varies widely. Some countries, like the Netherlands, allow the sale of psilocybin-containing truffles. Others, like Canada, have granted exemptions for therapeutic use. In most places, though, the substances commonly used for microdosing remain controlled, and possessing them carries legal risk regardless of the dose.